These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1750480)

  • 1. The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women.
    Ditkoff EC; Cassidenti DL; Paulson RJ; Sauer MV; Paul WL; Rivier J; Yen SS; Lobo RA
    Am J Obstet Gynecol; 1991 Dec; 165(6 Pt 1):1811-7. PubMed ID: 1750480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of a gonadotropin releasing hormone (GnRH) antagonist and exogenous gonadotropins to unstimulated in vitro fertilization (IVF) cycles: physiologic observations and preliminary experience.
    Paulson RJ; Sauer MV; Lobo RA
    J Assist Reprod Genet; 1994 Jan; 11(1):28-32. PubMed ID: 7949832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of administration of a gonadotropin-releasing hormone (GnRH) antagonist (Nal-Glu) during the periovulatory period: the luteinizing hormone surge requires secretion of GnRH.
    Dubourdieu S; Charbonnel B; D'Acremont MF; Carreau S; Spitz IM; Bouchard P
    J Clin Endocrinol Metab; 1994 Feb; 78(2):343-7. PubMed ID: 8106622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of intermittent and continuous use of a gonadotropin-releasing hormone antagonist (Nal-Glu) in in vitro fertilization cycles: a preliminary report.
    Cassidenti DL; Sauer MV; Paulson RJ; Ditkoff EC; Rivier J; Yen SS; Lobo RA
    Am J Obstet Gynecol; 1991 Dec; 165(6 Pt 1):1806-10. PubMed ID: 1750479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
    Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
    Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation.
    Frydman R; Cornel C; de Ziegler D; Taieb J; Spitz IM; Bouchard P
    Fertil Steril; 1991 Nov; 56(5):923-7. PubMed ID: 1936328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of corpus luteum function by the gonadotropin-releasing hormone antagonist Nal-Glu: effect of the dose and timing of human chorionic gonadotropin administration.
    Dubourdieu S; Charbonnel B; Massai MR; Marraoui J; Spitz I; Bouchard P
    Fertil Steril; 1991 Sep; 56(3):440-5. PubMed ID: 1894021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follicular arrest during the midfollicular phase of the menstrual cycle: a gonadotropin-releasing hormone antagonist imposed follicular-follicular transition.
    Kettel LM; Roseff SJ; Chiu TC; Bangah ML; Vale W; Rivier J; Burger HG; Yen SS
    J Clin Endocrinol Metab; 1991 Sep; 73(3):644-9. PubMed ID: 1908486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variable tolerance of the developing follicle and corpus luteum to gonadotropin-releasing hormone antagonist-induced gonadotropin withdrawal in the human.
    Hall JE; Bhatta N; Adams JM; Rivier JE; Vale WW; Crowley WF
    J Clin Endocrinol Metab; 1991 May; 72(5):993-1000. PubMed ID: 1902489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential regulation of luteinizing hormone, follicle-stimulating hormone, and free alpha-subunit secretion from the gonadotrope by gonadotropin-releasing hormone (GnRH): evidence from the use of two GnRH antagonists.
    Hall JE; Whitcomb RW; Rivier JE; Vale WW; Crowley WF
    J Clin Endocrinol Metab; 1990 Feb; 70(2):328-35. PubMed ID: 2105329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The synergistic effects of clomiphene citrate and human menopausal gonadotrophin in the folliculogenesis of stimulated cycles as assessed by the gonadotrophin-releasing hormone antagonist Nal-Glu.
    Cassidenti DL; Paulson RJ; Lobo RA; Sauer MV
    Hum Reprod; 1992 Mar; 7(3):344-8. PubMed ID: 1587939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibin A and inhibin B responses to gonadotropin withdrawal depends on stage of follicle development.
    Welt CK; Adams JM; Sluss PM; Hall JE
    J Clin Endocrinol Metab; 1999 Jun; 84(6):2163-9. PubMed ID: 10372726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous luteinizing hormone surges can be reliably prevented by the timely administration of a gonadotrophin releasing hormone antagonist (Nal-Glu) during the late follicular phase.
    Frydman R; Cornel C; de Ziegler D; Taieb J; Spitz IM; Bouchard P
    Hum Reprod; 1992 Aug; 7(7):930-3. PubMed ID: 1430131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effects of treatment with an LHRH antagonist on the ovulatory cycle are reduced when administered during the late follicular phase.
    Fraser HM
    Contraception; 1990 Jan; 41(1):73-83. PubMed ID: 2105873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerated dissolution of luteal-endometrial integrity by the administration of antagonists of gonadotropin-releasing hormone and progesterone to late-luteal phase women.
    Roseff SJ; Kettel LM; Rivier J; Burger HG; Baulieu E; Yen SS
    Fertil Steril; 1990 Nov; 54(5):805-10. PubMed ID: 2226914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of luteal function by a luteinizing hormone-releasing hormone antagonist during the early luteal phase in the stumptailed macaque monkey and the effects of subsequent administration of human chorionic gonadotropin.
    Fraser HM; Nestor JJ; Vickery BH
    Endocrinology; 1987 Aug; 121(2):612-8. PubMed ID: 3109885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486.
    Liu JH; Garzo G; Morris S; Stuenkel C; Ulmann A; Yen SS
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1135-40. PubMed ID: 2824550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent pituitary-gonadal axis suppression and extremely low anaphylactoid activity of a new gonadotropin releasing hormone (GnRH) receptor antagonist "azaline B".
    Campen CA; Lai MT; Kraft P; Kirchner T; Phillips A; Hahn DW; Rivier J
    Biochem Pharmacol; 1995 May; 49(9):1313-21. PubMed ID: 7763313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ablation of folliculogenesis in women by a single dose of gonadotropin-releasing hormone agonist: significance of time in cycle.
    Monroe SE; Henzl MR; Martin MC; Schriock E; Lewis V; Nerenberg C; Jaffe RB
    Fertil Steril; 1985 Mar; 43(3):361-8. PubMed ID: 3156770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of gonadotrophin-releasing hormone (GnRH) antagonist during the LH surge in normal women and during controlled ovarian hyperstimulation.
    Christin-Maitre S; Olivennes F; Dubourdieu S; Chabbert-Buffet N; Charbonnel B; Frydman R; Bouchard P
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):721-6. PubMed ID: 10848876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.